← Back to Screener
Rein Therapeutics, Inc. Common Stock (RNTX)
Price$0.94
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-47.86%
Price vs S&P 500 (4W)-22.69%
VGM Score22.67
Market Capitalization$80.67M
All Metrics
Book Value / Share (Quarterly)$0.41
P/TBV (Annual)8.92x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.59
Price vs S&P 500 (YTD)-26.86%
EPS (TTM)$-1.78
10-Day Avg Trading Volume0.46M
EPS Excl Extra (TTM)$-1.78
EPS (Annual)$-1.96
ROI (Annual)-294.78%
Cash / Share (Quarterly)$0.16
ROA (Last FY)-206.44%
EBITD / Share (TTM)$-1.82
ROE (5Y Avg)-126.55%
Cash Flow / Share (Annual)$-0.70
P/B Ratio6.96x
P/B Ratio (Quarterly)3.14x
Net Income / Employee (Annual)$-4,987,100
ROA (TTM)-124.25%
EPS Incl Extra (Annual)$-1.96
Current Ratio (Annual)0.70x
Quick Ratio (Quarterly)0.39x
3-Month Avg Trading Volume0.46M
52-Week Price Return-51.64%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.12
P/S Ratio (Annual)3.61x
Asset Turnover (Annual)1.39x
52-Week High$2.18
EPS Excl Extra (Annual)$-1.96
26-Week Price Return-39.93%
Quick Ratio (Annual)0.66x
13-Week Price Return-20.75%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.40x
Enterprise Value$81.15M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)14.72%
Cash / Share (Annual)$0.12
3-Month Return Std Dev96.75%
Net Income / Employee (TTM)$-5,020,800
ROE (Last FY)-294.78%
EPS Basic Excl Extra (Annual)$-1.96
Total Debt / Equity (Quarterly)0.42x
EPS Incl Extra (TTM)$-1.78
ROI (TTM)-157.35%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.12
Price vs S&P 500 (52W)-76.00%
Year-to-Date Return-18.70%
5-Day Price Return-11.86%
EPS Normalized (Annual)$-1.96
ROA (5Y Avg)-100.10%
Net Profit Margin (Annual)14.72%
Month-to-Date Return-15.04%
EBITD / Share (Annual)$-1.99
Operating Margin (Annual)14.68%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-126.55%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.78
P/TBV (Quarterly)8.92x
P/B Ratio (Annual)1.80x
Book Value / Share (Annual)$0.61
Price vs S&P 500 (13W)-29.00%
Beta1.37x
Revenue / Share (TTM)$0.00
ROE (TTM)-163.66%
52-Week Low$0.94
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.19est. -0.50
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RNTXRein Therapeutics, Inc. Common Stock | — | — | D | $0.94 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Rein Therapeutics develops therapies for orphan pulmonary and fibrosis indications with significant unmet medical need. The company has two Phase 2-ready candidates: LTI-03, a peptide for idiopathic pulmonary fibrosis, and LTI-01, a proenzyme for loculated pleural effusion—an indication with no approved treatments. Both programs have completed Phase 1b proof-of-concept and Phase 2a dose-ranging trials.